# A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

> **NCT03450018** · PHASE1,PHASE2 · TERMINATED · sponsor: **British Columbia Cancer Agency** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** SLC-0111
- **DRUG:** Gemcitabine Injection

## Key facts

- **NCT ID:** NCT03450018
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-10
- **Primary completion:** 2024-05-16
- **Final completion:** 2024-05-16
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450018, "A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03450018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*